Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1186/s12941-020-00402-x http://scihub22266oqcxt.onion/10.1186/s12941-020-00402-x 33256750!7702199!33256750     free     free     free       Ann+Clin+Microbiol+Antimicrob 2020 ; 19 (1): 56 Nephropedia Template TP {{tp|p=33256750|t=2020. COVID-19 vaccine development: What lessons can we learn from TB?|pdf=|usr=}}{{33256750}} gab.com Text COVID-19 vaccine development: What lessons can we learn from TB JO: Ann Clin Microbiol Antimicrob http://www.kidney.de/pget.php?&tw=1&pmid=33256750 #FOAvip At the time of writing, the SARS-CoV-2 virus has infected more than 49 million people causing more than 1.2 million deaths worldwide since its emergence from Wuhan, China in December 2019. Vaccine development against SARS-CoV-2 has drawn the global attention in order to stop the spread of the virus, with more than 10 vaccines being tested in phase III clinical trials, as of November 2020. However, critical to vaccine development is consideration of the immunological response elicited as well as biological features of the vaccine and both need to be evaluated thoroughly. Tuberculosis is also a major infectious respiratory disease of worldwide prevalence and the vaccine development for tuberculosis has been ongoing for decades. In this review, we highlight some of the common features, challenges and complications in tuberculosis vaccine development, which may also be relevant for, and inform, COVID-19 vaccine development. Twit Text FOAVip COVID-19 vaccine development: What lessons can we learn from TB ????Ann Clin Microbiol Antimicrob http://www.kidney.de/pget.php?&tw=1&pmid=33256750 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33256750 #FOAvip English Wikipedia <ref>{{Cite pmid|33256750}}</ref> COVID-19 vaccine development: What lessons can we learn from TB? #MMPMID33256750 Safar HA; Mustafa AS; McHugh TD Ann Clin Microbiol Antimicrob 2020[Nov]; 19 (1): 56 PMID33256750show ga At the time of writing, the SARS-CoV-2 virus has infected more than 49 million people causing more than 1.2 million deaths worldwide since its emergence from Wuhan, China in December 2019. Vaccine development against SARS-CoV-2 has drawn the global attention in order to stop the spread of the virus, with more than 10 vaccines being tested in phase III clinical trials, as of November 2020. However, critical to vaccine development is consideration of the immunological response elicited as well as biological features of the vaccine and both need to be evaluated thoroughly. Tuberculosis is also a major infectious respiratory disease of worldwide prevalence and the vaccine development for tuberculosis has been ongoing for decades. In this review, we highlight some of the common features, challenges and complications in tuberculosis vaccine development, which may also be relevant for, and inform, COVID-19 vaccine development. |COVID-19 Vaccines/adverse effects/*immunology[MESH] |COVID-19/etiology/*prevention & control/transmission[MESH] |Humans[MESH] |SARS-CoV-2/*immunology[MESH]COVID-19 vaccine development: What lessons can we learn from TB?(epmc).pdf DeepDyve Pubget Overpricing